Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
21/26/21	SEK 0.8190	0.00%	23,88,094
20/26/20	SEK 0.8190	-6.93%	48,79,923
19/26/19	SEK 0.8800	-2.22%	10,99,025
18/26/18	SEK 0.9000	-5.06%	12,03,549
17/26/17	SEK 0.9480	-2.77%	8,00,829

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 09:30:00 21/08/2026 pm IST			5-day change	1st Jan Change
0.8190 ^SEK	0.00%		-16.00%	-1.21%

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	17Cr 1.75Cr 1.5Cr 1.4Cr 1.29Cr 2.41Cr 167.69Cr 2.45Cr 6.47Cr 84Cr 6.58Cr 6.44Cr 278.62Cr	P/E 2026 *	-3.03x	P/E 2027 *	-2.16x
Enterprise Value	15Cr 1.58Cr 1.36Cr 1.27Cr 1.16Cr 2.18Cr 151.52Cr 2.21Cr 5.85Cr 76Cr 5.95Cr 5.82Cr 251.76Cr	EV / Sales 2026 *	4.78x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
24/06	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
12/06	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
08/06	Alzinova raises SEK 15.2 million before issuance costs	FW
26/05	Calendar Tuesday May 26	FW
25/05	Calendar Tuesday May 26	FW
21/05	Alzinova secures 80 percent of TO4 warrants	FW

20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
08/04	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
26/03	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/25/06	Alzinova gets fast track designation from US FDA	RE

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
20/08	Alzinova publishes interim report for the period January - June 2026	AQ
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
24/06	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ

1 week	-16.00%
Current month	-29.40%
1 month	+17.34%
3 months	+73.15%
6 months	+23.16%
Current year	-1.21%

1 week	0.75	1
1 month	0.71	1.23
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	0.00%	-16.00%	-43.05%	-75.77%	1.75Cr
LONZA GROUP AG	+1.09%	+5.26%	+4.52%	+26.24%	5.16TCr
REVOLUTION MEDICINES, INC.	-1.07%	+2.82%	+465.96%	+586.75%	4.49TCr
IQVIA HOLDINGS INC.	+1.47%	+9.79%	+35.92%	+21.40%	4.28TCr
BEONE MEDICINES AG	+1.44%	+7.77%	+19.38%	+92.75%	4.26TCr
CELLTRION, INC.	-0.93%	-4.33%	+16.18%	+53.76%	3.18TCr
MEDPACE HOLDINGS, INC.	+1.32%	+7.30%	+33.89%	+150.10%	1.73TCr
ASCENDIS PHARMA A/S	-0.60%	+1.93%	-	-	1.66TCr
EUROFINS SCIENTIFIC SE	+0.03%	+3.41%	+6.55%	+32.10%	1.48TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	+5.41%	+82.40%	+47.43%	1.41TCr
Average	+0.40%	+2.39%	+69.08%	+103.86%	2.76TCr
Weighted average by Cap.	+0.49%	+4.72%	+99.56%	+146.28%

	2026 *	2027 *
Net sales	3.14Cr 33.11L 28.36L 26.53L 24.29L 45.58L 32Cr 46.19L 1.22Cr 16Cr 1.24Cr 1.22Cr 53Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.5Cr -7L -17.35L -2.26Cr -17.65L -17.26L -7.47Cr	-7.7Cr -81.31L -69.65L -65.17L -59.66L -1.12Cr -78Cr -1.13Cr -3Cr -39Cr -3.05Cr -2.99Cr -129.27Cr
Net Debt	-1.6Cr -16.9L -14.47L -13.54L -12.4L -23.26L -16Cr -23.57L -62.39L -8.12Cr -63.44L -62.06L -27Cr	-1.9Cr -20.06L -17.19L -16.08L -14.72L -27.63L -19Cr -27.99L -74.09L -9.64Cr -75.34L -73.7L -32Cr